4-Methyl-2-(pyridin-3-yl)-oxazole | 118559-26-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-Methyl-2-(pyridin-3-yl)-oxazole
• 英文别名: 3-(4-methyloxazol-2-yl)-pyridine；4-Methyl-2-(3-pyridyl)-oxazole；4-methyl-2-pyridin-3-yl-1,3-oxazole
• CAS: 118559-26-5
• 化学式: C₉H₈N₂O
• 分子量: 160.175
• InChiKey: BDTMIZWDQMTNOF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-Methyl-2-(pyridin-3-yl)-oxazole 以2.8 g (0.016 mol, 46%)的产率得到4-Methyl-2-(1-methyl-1,2,5,6-tetrahydro-3-pyridyl)-oxazole, oxalate
  参考文献：
  名称：

  1,2,3-Triazole and tetrazole substituted piperidine or

  摘要：

  本发明涉及以下式的新化合物，其中虚线表示可选键：##STR1##其中“het”表示一个五元杂环，可能包括1或2个双键和1-4个从氮、氧或硫中选择的杂原子，但“het”不能表示1,2,4-或1,3,4-噁二唑；R.sup.1选择自氢、较低的烷基，可选地取代为苯基，苯基可能被卤素、较低的烷基或较低的烷氧基取代，或者是一个基团R.sup.6--CO--NH--CH.sub.2--或R.sup.6--O--CO--，其中R.sup.6是较低的烷基、支链或直链，或者是可选地取代为卤素、三氟甲基、较低的烷基、羟基、较低的烷氧基或较低的酰氧基的苯基；R.sup.2和R.sup.3相同或不同，各自代表氢、较低的烷基、环烷基（3-6个碳原子）、较低的烯基、较低的烷二烯基、较低的炔基，可选地取代为羟基、卤素或苯基，其中苯基可能被卤素、三氟甲基、较低的烷基、羟基或较低的烷氧基取代；R.sup.2和R.sup.3还可以分别选择三氟甲基或可选地取代为卤素、三氟甲基、较低的烷基、羟基、较低的烷氧基或较低的酰氧基的苯基，或者R.sup.2和R.sup.3可以分别是一个基团OR.sup.7或SR.sup.7，其中R.sup.7定义为R.sup.2或R.sup.3，如果“het”包括2个或更多个碳原子，则R.sup.4和R.sup.5相同或不同，各自定义为R.sup.2或R.sup.3，如果“het”只包括一个碳原子，则在杂环上只有一个取代基R.sup.4，R.sup.4定义为R.sup.2或R.sup.3，以及其单独的立体异构体和药学上可接受的酸盐。此外，本发明还涉及制备式I化合物的方法，新的中间体，含有相同化合物的药物组合物，以及通过给予式I化合物的非毒性有效量来治疗由乙酰胆碱（AcCh）或肌碱系统功能障碍引起的疾病的方法。

  公开号：

  US04866077A1
• 作为产物：
  描述：

  4-甲基恶唑 、 3-溴吡啶 生成 4-Methyl-2-(pyridin-3-yl)-oxazole
  参考文献：
  名称：

  Palladium-Catalyzed Coupling of Oxazol-2-yl- and 2-Oxazolin-2-yltrimethylstannanes with Aromatic Halides. A New Entry to 2-Aryl and 2-Heteroaryl Oxazoles and Oxazolines

  摘要：

  4-甲基恶唑和4,4-二甲基-2-恶唑啉用正丁基锂和三甲基氯化锡反应得到相应的2-三甲基甲锡烷基衍生物，在四(三苯基膦)钯(0)催化剂存在下发生交叉偶联与各种芳基和杂芳基卤化物反应，以高产率得到2-芳基和2-杂芳基恶唑和恶唑啉。

  DOI：

  10.1055/s-1987-28047

文献信息

• HIV protease inhibiting compounds
  申请人：DeGoey A. David

  公开号：US20050148623A1

  公开（公告）日：2005-07-07

  A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

  披露了一种公式的化合物作为HIV蛋白酶抑制剂。还披露了用于抑制HIV感染的方法和组合物。
• [EN] INDOLIN-2-ONE AND 1,3-DIHYDRO-PYRROLO[3,2-c]PYRIDIN-2-ONE DERIVATIVES<br/>[FR] DÉRIVÉS D'INDOLIN-2-ONE ET DE 1,3-DIHYDRO-PYRROLO[3,2-C]PYRIDIN-2-ONE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015177110A1

  公开（公告）日：2015-11-26

  The present invention is concerned with indolin-2-one and l,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives of general formula (I) wherein Ar1 is phenyl, pyridinyl or pyrimidinyl; Ar2 is a 5 or 6 membered heteroaryl group, containing 2 or 3 heteroatoms, selected from N, O or S; R1 is hydrogen, lower alkyl, halogen or lower alkoxy; R2 is hydrogen or lower alkyl; R3 is hydrogen, lower alkyl, lower alkyl substituted by hydroxy, cycloalkyl, oxetan-3-yl, pyridinyl, imidazolyl, pyrazolyl, pyrimidinyl, which rings may optionally substituted by lower alkyl, or is -(CH2)3-S(O)2-cyclopropyl; X is CH or N; n is 1 or 2; as well as with a pharmaceutically acceptable salts thereof, with a racemic mixture, or with its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof, for use in the treatment of certain central nervous system disorders which are positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, Alzheimer's disease, autism, Parkinson's disease, chronic pain, borderline personality disorder, sleep disturbances, chronic fatigue syndrome, stiffness, antiinflammatory effects in arthritis and balance problems.

  本发明涉及一般式(I)的吲哚啉-2-酮和1,3-二氢吡咯并[3,2-c]吡啶-2-酮衍生物，其中Ar1是苯基、吡啶基或嘧啶基；Ar2是含有2个或3个N、O或S杂原子的5或6元杂芳基团；R1是氢、低碳基、卤素或低烷氧基；R2是氢或低碳基；R3是氢、低碳基、低碳基取代的羟基、环烷基、氧杂环丙烯基、吡啶基、咪唑基、吡唑基、嘧啶基，这些环可能被低碳基取代，或者是-(CH2)3-S(O)2-环丙基；X是CH或N；n为1或2；以及其药学上可接受的盐、消旋混合物、对映体和/或光学异构体和/或立体异构体，用于治疗某些中枢神经系统疾病，包括精神病（正性症状和负性症状）、精神分裂症、物质滥用、酒精和药物成瘾、强迫症、认知障碍、双相情感障碍、情绪障碍、重度抑郁症、治疗难治性抑郁症、焦虑症、阿尔茨海默病、自闭症、帕金森病、慢性疼痛、边缘性人格障碍、睡眠障碍、慢性疲劳综合征、僵硬、关节炎中的抗炎作用和平衡问题。
• Derivatives of 1,2,5,6-tetrahydropyridine substituted by a thiazolyl or
  申请人：Roussel Uclaf

  公开号：US05053416A1

  公开（公告）日：1991-10-01

  Compounds of formula (I) ##STR1## in which X represents oxygen or sulphur, R.sub.1 represents hydrogen, a linear, branched or cyclic alkyl containing up to 8 carbon atoms, an alkenyl or alkynyl containing up to 6 carbon atoms, hydroxyl, an OCOalk.sub.1 radical in which alk.sub.1 represents alkyl containing up to 6 carbon atoms, an OCONHalk.sub.2 radical in which alk.sub.2 represents alkyl containing up to 6 carbon atoms, a CO.sub.2 alk.sub.3 radical in which alk.sub.3 represents alkyl or alkenyl containing up to 6 carbon atoms, an Oalk.sub.4 radical in which alk.sub.4 represents alkyl containing up to 6 carbon atoms, an OCOAr.sub.1, OCONHAr.sub.2 or CO.sub.2 Ar.sub.3 radical in which Ar.sub.1, Ar.sub.2 or Ar.sub.3 represents aryl containing up to 14 carbon atoms, R.sub.2 represents hydrogen, a linear, branched or cyclic alkyl containing up to 6 carbon atoms, alkenyl or alkynyl containing up to 6 carbon atoms, an alkoxyalkyl alk'.sub.1 Oalk'.sub.2 radical in which alk'.sub.1 and alk'.sub.2 represent alkyl containing up to 6 carabon atoms, hydroxyalkyl in which the alkyl contains up to 6 carbon atoms or aryl containing up to 14 carbon atoms, as well as their addition salts with organic or mineral acids, which compounds are useful in the treatment of patients suffering from Alzheimer's disease, senile dementia or memory disorders of the aged; also, compositions containing the same, method of use, method of preparation, and intermediates therefor.

  化合物的式子(I) ##STR1## 其中X代表氧或硫，R.sub.1代表氢，线性、支链或环烷基，含有高达8个碳原子，烯基或炔基，含有高达6个碳原子，羟基，OCOalk.sub.1基团，其中alk.sub.1代表含有高达6个碳原子的烷基，OCONHalk.sub.2基团，其中alk.sub.2代表含有高达6个碳原子的烷基，CO.sub.2 alk.sub.3基团，其中alk.sub.3代表含有高达6个碳原子的烷基或烯基，Oalk.sub.4基团，其中alk.sub.4代表含有高达6个碳原子的烷基，OCOAr.sub.1，OCONHAr.sub.2或CO.sub.2 Ar.sub.3基团，其中Ar.sub.1，Ar.sub.2或Ar.sub.3代表含有高达14个碳原子的芳基，R.sub.2代表氢，线性、支链或环烷基，含有高达6个碳原子，烯基或炔基，含有高达6个碳原子，alkoxyalkyl alk'.sub.1 Oalk'.sub.2基团，其中alk'.sub.1和alk'.sub.2代表含有高达6个碳原子的烷基，含有高达6个碳原子的烷基的羟基烷基或含有高达14个碳原子的芳基，以及它们与有机或无机酸的加成盐，这些化合物在治疗患有阿尔茨海默病、老年性痴呆或老年人记忆障碍的患者中有用；此外，还包括含有相同化合物的组合物，使用方法，制备方法和中间体。
• Oxazole and thiazole derivatives and their use for treating disorders
  申请人：H. Lundbeck A/S

  公开号：US04925858A1

  公开（公告）日：1990-05-15

  The present invention relates to novel compounds of the following formula, where the dotted line designates an optional bond: ##STR1## wherein "het" designates a five membered heterocyclic ring which may include 1 or 2 double bonds and 1-4 heteroatoms selected from nitrogen, oxygen or sulphur, provided that "het" may not designate a 1,2,4- or 1,3,4-oxadiazole; R.sup.1 -R.sup.5 are as defined in the specification; as well as individual stereo isomers and pharmaceutically acceptable acid addition salts thereof. The invention moreover relates to methods for the preparation of the compounds of formula I, to novel intermediates, to pharmaceutical compositions containing same and to methods for the treatment of disorders, caused by malfunction of the acetylcholine (AcCh) or muscarinic system, by administering a non-toxic effective amount of a compound of formula I.

  本发明涉及以下式子的新化合物，其中点线表示可选键：##STR1## 其中“het”表示一个五元杂环环，可以包括1或2个双键和1-4个从氮、氧或硫中选择的杂原子，但“het”不能表示1,2,4-或1,3,4-噁二唑；R.sup.1-R.sup.5如规范中所定义；以及其个别立体异构体和药学上可接受的酸加成盐。此外，本发明还涉及制备式I化合物的方法、新的中间体、包含其的药物组合物以及通过给予式I化合物的非毒性有效量治疗因乙酰胆碱（AcCh）或肌动系统功能障碍而引起的疾病的方法。
• 1,2,3-triazole and tetrazole substituted piperidine or
  申请人：H. Lundbeck, A/S

  公开号：USRE036374E1

  公开（公告）日：1999-11-02

  The present invention relates to novel compounds of the following formula, where the dotted line designates in optional bond: ##STR1## wherein "het" designates a five membered heterocyclic ring which may include 1 or 2 double bonds and 1-4 heteroatoms selected from nitrogen, oxygen or sulphur, provided that "het" may not designate a 1,4- or 1,3,4-oxadiazole, R.sup.1 is selected from hydrogen, lower alkyl, optionally substituted with phenyl which may be substituted with halogen, lower alkyl, or lower alkoxy, or a group R.sup.6 --CO--NH--CH.sub.2 -- or R.sup.6 --O--CO--, wherein R.sup.6 is lower alkyl, branched or unbranched, or phenyl optionally substituted with halogen, trifuoromethyl, lower alkyl, hydroxy, lower alkoxy, or lower acyloxy; R.sup.2 and R.sup.3 are the same or different, each representing hydrogen, lower alkyl, cycloalkyl (3-6 C-atoms), lower alkenyl, lower alkadienyl, lower alkynyl, optionally substituted with hydroxy, halogen or phenyl, in which the phenyl group may be substituted with halogen, trifluoromethyl, lower alkyl, hydroxy or lower alkoxy; R.sup.2 and R.sup.3 may further, respectively, be selected from trifluoromethyl or phenyl optionally substituted with halogen, trifluoromethyl, lower alkyl, hydroxy, lower alkoxy or lower acyloxy, or R.sup.2 and R.sup.3 may, respectively, be a group OR.sup.7 or SR.sup.7 wherein R.sup.7 is defined as R.sup.2 or R.sup.3, and if "het" includes 2 or more carbon atoms R.sup.4 and R.sup.5 are the same or different, and each is defined as R.sup.2 or R.sup.3, and if "het" includes only one carbon atom, there is only one substituent, R.sup.4, on the heterocyclic ring, and R.sup.4 is defined as R.sup.2 or R.sup.3, as well as individual stereo isomers and pharmaceutically acceptable acid addition salts thereof. The invention moreover relates to methods for the preparation of the compounds of formula 1, to novel intermediates, to pharmaceutical compositions containing same and to methods for the treatment of disorders, caused by malfunction of the acetylcholine (AcCh) or muscarinic system, by administering a non-toxic effective amount of a compound of formula I.

  本发明涉及以下式的新化合物，其中点线表示可选键：##STR1##其中“het”表示一个五元杂环环，可以包括1或2个双键和1-4个从氮、氧或硫中选择的杂原子，前提是“het”不能表示1,4-或1,3,4-噁二唑，R.sup.1选择自氢、较低的烷基，可选地取代为苯基，苯基可以取代为卤素、较低的烷基或较低的烷氧基，或者是一个R.sup.6 -CO-NH-CH.sub.2-或R.sup.6-O-CO-基团，其中R.sup.6是较低的烷基，分支或非分支，或苯环，可选地取代为卤素、三氟甲基、较低的烷基、羟基、较低的烷氧基或较低的酰氧基；R.sup.2和R.sup.3相同或不同，每个表示氢、较低的烷基、环烷基（3-6个碳原子）、较低的烯基、较低的烷二烯基、较低的炔基，可选地取代为羟基、卤素或苯基，在其中苯基可以取代为卤素、三氟甲基、较低的烷基、羟基或较低的烷氧基；R.sup.2和R.sup.3可以进一步分别选择三氟甲基或苯基，可选地取代为卤素、三氟甲基、较低的烷基、羟基、较低的烷氧基或较低的酰氧基，或R.sup.2和R.sup.3可以分别是OR.sup.7或SR.sup.7基团，其中R.sup.7定义为R.sup.2或R.sup.3，如果“het”包括2个或多个碳原子，则R.sup.4和R.sup.5相同或不同，每个定义为R.sup.2或R.sup.3，如果“het”仅包括一个碳原子，则杂环环上只有一个取代基R.sup.4，定义为R.sup.2或R.sup.3，以及其个别立体异构体和药学上可接受的酸加合物。此外，本发明还涉及制备公式1化合物的方法、新的中间体、含有同样化合物的制药组合物以及通过给予公式I化合物的非毒性有效量治疗由乙酰胆碱（AcCh）或肌动系统功能不良引起的疾病的方法。